New combo therapy targets liver tumors directly

NCT ID NCT06311851

First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 21 times

Summary

This study tests a new way to treat liver metastases by combining a drug called bevacizumab with a procedure called TACE, which delivers chemotherapy directly to the liver. The goal is to see if this combination helps patients live longer and shrinks tumors better than TACE alone. About 40 adults with liver metastases that cannot be surgically removed will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Pardis Noor Medical Imaging and Cancer Center

    RECRUITING

    Tehran, Tehran Province, 021, Iran

    Contact

Conditions

Explore the condition pages connected to this study.